Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.38 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.35 |
| ▸ | DPP4 | P27487 | 1/20 | 0.31 |
| ▸ | COMT | P21964 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14412626 | 0.83 | GRIN2D (0.34) | — | |
| SCHEMBL844430 | 0.79 | TSHR (0.31) | — | |
| SCHEMBL7599670 | 0.79 | SLC7A5 (0.44) | SLC7A5PSMB5DPP4COMT | |
| SCHEMBL17833247 | 0.78 | DPP4 (0.33) | DPP4 | |
| SCHEMBL17833080 | 0.78 | DPP4 (0.33) | DPP4 | |
| SCHEMBL9506659 | 0.77 | SLC7A5 (0.45) | SLC7A5DPP4 | |
| SCHEMBL14351293 | 0.77 | TP53 (0.32) | — | |
| SCHEMBL19420430 | 0.77 | SLC7A5 (0.42) | SLC7A5PSMB5DPP4COMT | |
| SCHEMBL12286895 | 0.77 | SLC7A5 (0.42) | SLC7A5PSMB5DPP4COMT | |
| SCHEMBL14412755 | 0.77 | TP53 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0041047-A2 | Dioxide compounds, process for their preparation and their use | CIBA-GEIGY AG (CH) | 1981-12-02 | — | — | EP | claimed |
| US-20130005730-A1 | NOVEL 1,3-OXAZOLIDINE COMPOUNDS AND THEIR USE AS RENIN INHIBITORS | MEDIVIR AB (SE) | 2013-01-03 | — | — | US | disclosed |
| EP-2499120-A1 | NOVEL 1,3-OXAZOLIDINE COMPOUNDS AND THEIR USE AS RENIN INHIBITORS | Novadex Pharmaceuticals AB (SE) | 2012-09-19 | — | — | EP | disclosed |
| WO-2011056126-A1 | NOVEL 1,3-OXAZOLIDINE COMPOUNDS AND THEIR USE AS RENIN INHIBITORS | NOVADEX PHARMACEUTICALS AB (SE) | 2011-05-12 | — | — | WO | disclosed |
| EP-0278911-B1 | BICYCLIC BETA-LACTAM CARBOXYLIC ACIDS | CIBA-GEIGY AG (CH) | 1993-08-04 | — | — | EP | disclosed |
| EP-0246187-B1 | 2-PYRIDYL PENEM COMPOUNDS | CIBA-GEIGY AG (CH) | 1992-02-05 | — | — | EP | disclosed |
| US-4965260-A | PENICILLINS | CIBA-GEIGY CORPORATION (US) | 1990-10-23 | — | — | US | disclosed |
| EP-0166697-B1 | AROYL SUBSTITUTED DIHYDRO-1,4-THIAZINES | CIBA-GEIGY AG (CH) | 1990-05-09 | — | — | EP | disclosed |
| US-4826832-A | BACTERICIDES | CIBA-GEIGY CORPORATION (US) | 1989-05-02 | — | — | US | disclosed |
| EP-0297042-A1 | Substituted penem compounds | CIBA-GEIGY AG (CH) | 1988-12-28 | — | — | EP | disclosed |
| EP-0046734-A2 | Aminohydroxyphenyl derivatives of cephalosporins, process for their preparation and pharmaceutical compositions containing them | CIBA-GEIGY AG (CH) | 1982-03-03 | — | — | EP | disclosed |
| US-4313945-A | 7-Thiazolyl-acetamido-cephem derivatives with terminal aminocarboxylic acid grouping | CIBA-GEIGY CORPORATION (US) | 1982-02-02 | — | — | US | disclosed |
| EP-0041047-A2 | Dioxide compounds, process for their preparation and their use | CIBA-GEIGY AG (CH) | 1981-12-02 | — | — | EP | disclosed |
| EP-0037797-A2 | Cephalosporin derivatives, process for their preparation, pharmaceutical compositions containing them and their application | CIBA-GEIGY AG (CH) | 1981-10-14 | — | — | EP | disclosed |
| EP-0031794-A2 | Cephalosporin derivatives, process for their preparation and pharmaceutical compositions containing them | CIBA-GEIGY AG (CH) | 1981-07-08 | — | — | EP | disclosed |
| EP-0025017-A1 | Polyazathia compounds, process for their preparation, pharmaceutical preparations containing such compounds and use of the latter | CIBA-GEIGY AG (CH) | 1981-03-11 | — | — | EP | disclosed |
| EP-0022245-A2 | Aminothiadiazolyl derivatives, process for their preparation, pharmaceutical compositions containing them;starting compounds and process for their preparation | CIBA-GEIGY AG (CH) | 1981-01-14 | — | — | EP | disclosed |
| EP-0016900-A1 | Intermediates in the preparation of cephalosporin derivatives, process for their preparation and use | CIBA-GEIGY AG (CH) | 1980-10-15 | — | — | EP | disclosed |
| EP-0015240-A1 | Azacyclyl (thio) ureidoacetyl compounds and their preparation | CIBA-GEIGY AG (CH) | 1980-09-03 | — | — | EP | disclosed |
| EP-0000500-A2 | Cephalosprin derivatives, process for their preparation and pharmaceutical compositions containing them | CIBA-GEIGY AG (CH) | 1979-02-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130005730-A1 | NOVEL 1,3-OXAZOLIDINE COMPOUNDS AND THEIR USE AS RENIN INHIBITORS | REN, AGTR1, ACE | SLC7A5 1890/4885PSMB5 735/4885DPP4 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.